R
Roivant Sciences Ltd. (ROIV)
NMS – Real vaqt narxi. Valyuta: USD
34.07
+0.05 (0.15%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
34.07
0.00 (0.00%)
Bozordan keyin: Jun 26, 2026, 5:25 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
34.07
+0.05 (0.15%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
34.07
0.00 (0.00%)
Bozordan keyin: Jun 26, 2026, 5:25 PM EDT
Roivant Sciences Ltd., klinik bosqichdagi biofarmatsevtika kompaniyasi, dori-darmonlar va texnologiyalarni kashf etish, ishlab chiqish va tijoratlashtirishga qaratilgan. Uning klinik mahsulot nomzodlari orasida IMVT-1402, FcRn-ga qaratilgan to'liq inson monoklonal antikori, bir nechta IgG vositali otoimmün ko'rsatkichlar bo'ylab ishlab chiqilmoqda; mosliciguat, o'pka gipertenziyasi uchun ishlab chiqilayotgan inhalatsiyalangan sGC aktivator, shu jumladan interstitsial o'pka kasalligi; neonatal fragment kristallanadigan retseptor, Graves kasalligi, davolash qiyin bo'lgan revmatoid artrit, Sjögren kasalligi, miyasteniya gravis, surunkali yallig'lanishli demiyelinatsiyalovchi polinevropatiya va teri lyupus eritematozi ko'rsatkichlarini davolash uchun; batoclimab, qalqonsimon bezning ko'z kasalligini davolash uchun to'liq inson monoklonal antikori; va brepocitinib, TYK2 va JAK1 ning kuchli kichik molekulyar inhibitori, dermatomiyozit, yuqumli bo'lmagan uveit, teri sarkoidozi va boshqa immunitet vositali kasalliklarni davolash uchun ishlab chiqilmoqda. Kompaniyaning asosiy dasturi mosliciguatni o'z ichiga oladi, bu o'pka gipertenziyasi, shu jumladan interstitsial o'pka kasalligi va boshqa kardiopulmonar kasalliklarni davolash uchun inhalatsiyalangan sGC aktivatoridir. Bundan tashqari, kompaniya lipid nanozarra (LNP) platformasi va ligand konjugat platformasini o'z ichiga olgan etkazib berish platformalarini taklif etadi. Roivant Sciences Ltd. 2014 yilda tashkil etilgan va Buyuk Britaniyaning London shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Eric Venker M.D., Pharm.D. | President & CEO of Immunovant |
| Dr. Frank M. Torti M.B.A., M.D. | President & Vant Chair |
| Dr. Huafeng Xu Ph.D. | Chief Technology Officer |
| Dr. Mayukh Sukhatme M.D. | President, Chief Investment Officer & Director |
| Mr. Ian Rosenblum | Chief Information Officer |
| Mr. Josh Chen J.D. | General Counsel |
| Mr. Matthew Gline | CEO & Director |
| Mr. Richard Pulik | Chief Financial Officer |
| Ms. Jennifer Humes | Chief Accounting Officer |
| Ms. Kelly Graff | Head of People |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-20 | S-8 | dp242198_s8.htm |
| 2026-05-20 | 10-K | roiv-20260331.htm |
| 2026-04-02 | 8-K | ef20069685_8k.htm |
| 2026-03-23 | 8-K/A | ef20068452_8ka.htm |
| 2026-03-03 | 8-K | ef20066998_8k.htm |
| 2026-02-06 | 8-K | roiv-20260206.htm |
| 2026-02-06 | 10-Q | roiv-20251231.htm |
| 2025-12-11 | 8-K | ef20061071_8k.htm |
| 2025-11-10 | 8-K | ef20058314_8k.htm |
| 2025-11-10 | 10-Q | roiv-20250930.htm |